We want to make it easy for our patients to manage and navigate the financial toxicity they encounter from their cancer care, noted Mike Koroscik, MBA, MHA, vice president of oncology, Allina Health and the Allina Health Cancer Institute.
We want to make it easy for our patients to manage and navigate the financial toxicity they encounter from their cancer care, and for that we provide foundation and copay assistance, as well as look at optimizing insurance coverage, noted Mike Koroscik, MBA, MHA, vice president of oncology, Allina Health and the Allina Health Cancer Institute.
Transcript
Can you discuss some initiatives Allina Health has to address financial toxicity in oncology?
I’m passionate about addressing the financial toxicity of cancer care. I can't control the cost of drugs and oftentimes, too, just the cost of health care, even though that is an impediment, too, of addressing the total cost of care. But what I'm proud to roll out is a robust and comprehensive patient financial navigation program. It's not only maximizing, for our patients, the use of outside foundation and copay assistance, but it's also looking at insurance optimization and other aspects to decrease the financial toxicity. We know from our internal studies, too, that our patients’ anxiety is higher around the financial aspects than it is even over the diagnosis itself.
So my goal is at all of our sites, both virtually and in person, to elevate through our software to make it easy to manage and navigate all the foundations to address the financial toxicity, which is also a population health initiative, too.
Trump Directs Pharma Companies on Cutting Drug Prices Under Most-Favored-Nation Order
July 31st 2025President Donald Trump has sent letters to pharmaceutical companies, aiming to compel them to lower drug prices in the US to match the lowest prices offered in other developed nations, a move that could significantly reduce costs and disrupt the current system of pharmacy benefit managers.
Read More
Linvoseltamab Added as Preferred Agent in Newest MM Practice Guidelines
July 31st 2025On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory multiple myeloma (MM), and the most recent update to the National Comprehensive Cancer Network guidelines for MM has added the BCMA-targeted bispecific antibody as a preferred treatment option.
Read More
Trump Directs Pharma Companies on Cutting Drug Prices Under Most-Favored-Nation Order
July 31st 2025President Donald Trump has sent letters to pharmaceutical companies, aiming to compel them to lower drug prices in the US to match the lowest prices offered in other developed nations, a move that could significantly reduce costs and disrupt the current system of pharmacy benefit managers.
Read More
Linvoseltamab Added as Preferred Agent in Newest MM Practice Guidelines
July 31st 2025On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory multiple myeloma (MM), and the most recent update to the National Comprehensive Cancer Network guidelines for MM has added the BCMA-targeted bispecific antibody as a preferred treatment option.
Read More
2 Commerce Drive
Cranbury, NJ 08512